Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA.
Nat Rev Microbiol. 2018 Oct;16(10):594-600. doi: 10.1038/s41579-018-0039-7.
The recent epidemic of Zika virus (ZIKV) in the Americas has revealed the devastating consequences of ZIKV infection, particularly in pregnant women. Congenital Zika syndrome, characterized by malformations and microcephaly in neonates as well as developmental challenges in children, highlights the need for the development of a safe and effective vaccine. Multiple vaccine candidates have been developed and have shown promising results in both animal models and phase I clinical trials. However, important challenges remain for the clinical development of these vaccines. In this Progress article, we discuss recent preclinical studies and lessons learned from first-in-human clinical trials with ZIKV vaccines.
近期美洲的寨卡病毒(ZIKV)疫情揭示了 ZIKV 感染的毁灭性后果,特别是对孕妇而言。先天性寨卡综合征的特征是新生儿出现畸形和小头畸形,以及儿童发育挑战,这凸显了开发安全有效的疫苗的必要性。已经开发出多种疫苗候选物,并且在动物模型和 I 期临床试验中均显示出有希望的结果。然而,这些疫苗的临床开发仍然存在重要挑战。在这篇进展文章中,我们讨论了最近的临床前研究以及从 ZIKV 疫苗的首次人体临床试验中吸取的经验教训。